Abstract:Fabrizio Martora, 1 Claudio Marasca, 2 Sara Cacciapuoti, 1 Federica Fariello, 1 Luca Potestio, 1 Teresa Battista, 1 Massimiliano Scalvenzi, 1 Matteo Megna 1 1 Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2 Dermatology Unit, Medical Department, "Antonio Cardarelli" National Hospital, Naples, Italy Correspondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Naples, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 – 7462442, Email Background: The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes. Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting. Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4%. Conclusion: The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon. Keywords: hidradenitis suppurativa, secukinumab, adalimumab, treatments Hidradenitis suppurativa (HS), is a chronic, inflammatory, recurrent and debilitating skin disease affecting hair follicles, the manifestations are characterized by inflammatory, painful and localized lesions in body districts where apocrine glands are present. 1,2 The underlying pathogenic mechanism of HS is not yet known certainly follicular hyperkeratosis within the pilosebaceous-apocrine unit represents the initial lesion. New studies show new insights into the role of pro-inflammatory cytokines in the pathogenesis of HS, helping to fill some existing gaps in the knowledge of the development of this pathology. 3,4 The treatment of HS has always been a real challenge for dermatologists; to date, the first FDA biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, whose approval dates to 2015. Several real-life studies highlight a mean clinical success rate of about 60%. 5–8 However, primary or secondary lack of efficacy may occur. 9–13 Secukinumab, an anti-interleukin 17A drug approved for moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis has shown effective results in clinical trials improving signs and symptoms of HS with a good safety profile and response up to 52 weeks. 14 Even few real-life data are already in line with the studies carried out. 14 Recently, European Commission (EC) has approved secukinumab, for use in adults with active moderate to severe HS and an inadequate response to conventional systemic HS therapy, 15 while FDA approval has been reached recently (31 October 2023). The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes. Indeed, different new drugs are being tested for HS (eg, spesolimab and porvocitinib). It is therefore important for the future to select new therapeutic targets for HS establishing a universally and shared treatment algorithm. Among future drugs, secukinumab certainly represents the most immediate novelty. We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting. The inclusion criteria followed the criteria established during the clinical trials conducted for HS. 15,16 Inclusion criteria were: i) age ≥ 18 years; ii) diagnosis of moderate to severe HS (Hurley II or III); particularly eligible patients were required to be diagnosed at least 1 year before the baseline visit and have a total abscess and inflammatory nodule (AN) count ≥ 3 at baseline, HS lesions in ≥ 2 distinct anatomical locations, a draining fistula count ≤ 20 at baseline, and inadequate response to oral antibiotics for the treatment of HS. iii) Adalimumab primary or -Abstract Truncated-

Real‐world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Expanding the frontiers of therapeutic options in hidradenitis suppurativa: The valid contribution of bimekizumab

Bimekizumab for the treatment of hidradenitis suppurativa

P080 Bimekizumab efficacy and impact on pain in moderate-to-severe hidradenitis suppurativa: results from BE HEARD I and II

Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa

Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab

P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

Real‐world adalimumab survival and discontinuation factors in hidradenitis suppurativa

P106 Clinical outcomes and quality of life in a cross-sectional study of patients with moderate-to-severe psoriasis treated with bimekizumab in routine clinical practice

Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

Assessing the Role of Adalimumab in Treating Hidradenitis Suppurativa: Findings from a Retrospective Study at a Reference Center

Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study

The Efficacy and Safety of Biosimilars in Hidradenitis Suppurativa: A Comprehensive Review

Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials

Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study